The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients

Sponsor
An-Najah National University
Study ID
NCT04923295
Status
Completed

Conditions

  • Peritoneal Dialysis Complication
  • Ultrafiltration Failure

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 10Mg Tab — DRUG
    Effect of Dapagliflozin on ultrafiltration and PET results among peritoneal dialysis patients

Study Details

Patients with average or high average peritoneal glucose transport status be included in the study as mentioned in the inclusion and exclusion criteria. The change in peritoneal glucose transport will be evaluated before and after one month treatment with 10 mg of Dapagliflozin. Peritoneal Equilibration Test (PET) test for patients before and after Dapagliflozin use and volume status of patients as measured by ultrafiltration from peritoneal dialysis exchanges. The aim of the trial is to determine whether dapagliflozin can decrease glucose absorption from peritoneal fluid and reduce plasma glucose absorption from the PD fluid and thus improve ultrafiltration with a reduction in intraperitoneal glucose exposure

Key Dates

Start date
Jun 2, 2021
Status verified
Oct 2022
Primary completion
Jul 28, 2021
Completion
Jul 28, 2021

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pre Treatment and post treatment
    Patients on Peritoneal Dialysis will be evaluated by PET and transport status Patients on Peritoneal Dialysis will be evaluated by PET after treatment with Dapagliflozin

Primary Outcome Measure

Change from Baseline in the Mean Peritoneal Fluid Glucose ratio (D4/D0) after 4 Weeks of Treatment with 10 mg of Dapagliflozin [ Time Frame: 4 weeks ]

Related Studies